The world’s largest generic drugmaker earned 58 cents per diluted share excluding one-time items in the July-September period, down from 68 cents a year earlier. Revenue fell 6% to $4.26 billion due to generic competition for its multiple sclerosis drug Copaxone and declines in sales in the United States, Russia and Japan, although it posted gains in some of its newly launched drugs. Analysts had forecast Israel-based Teva would earn 59 cents a share ex-items on revenue of $4.24 billion, according to I/B/E/S data from Refinitiv. …read more
Source:: Yahoo Finance
